initial public offerings (IPOs) trading on American exchanges

Monday, July 31, 2017

Novan (NOVN) : 10-month performance

  • The company will host a conference call next Wednesday, August 2, to update investors on its activities and progress.
  • Several months ago, it reported positive results from a mid-stage study of SB208, a topical treatment for certain fungal infections. Shares plummeted in January after lead product candidate SB204 showed less-than-expected results in a late-stage acne study.
  • Previously: Novan reports positive topline results with SB208 in Phase 2 trial; shares ahead 50% premarket (April 12)
  • Previously: Novan's lead product product shows mixed results in pivotal studies; shares plummet 76% (Jan. 27)


Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.


4105 Hopson Rd
MORRISVILLE, NC 27560-9018
United States 

Key stats and ratios

Q1 (Mar '17)2016
Net profit margin-11607.00%-
Operating margin-11377.00%-
EBITD margin--
Return on average assets-92.15%-116.73%
Return on average equity-179.76%-

No comments:

Post a Comment